

# MNKD Products & Pipeline

■ Cardiometabolic
 ■ Orphan Lung

Product	Targeted Indications	Pre-IND	Phase 1	Phase 2	Phase 3	Approval
<b>Afrezza® (insulin human) Inhalation Powder</b>	<b>T1DM / T2DM</b> (aged 6 and older)					Marketed
<b>V-Go® All-in-One Insulin Delivery Patch</b>	<b>T1DM / T2DM</b> (adults)					Marketed
<b>FUROSCIX® (furosemide injection)</b> <small>(marketed by scPharmaceuticals, a wholly owned subsidiary of MannKind)</small>	Edema from <b>CHF / CKD</b>					Marketed
<b>FUROSCIX ReadyFlow™ Autoinjector</b>	Edema from <b>CHF / CKD</b>					PDUFA: Q3 2026
<b>Bumetanide DPI</b> <small>(MNKD-701)</small>	Edema from <b>CHF / CKD</b>	Pre-Clinical				
<b>Tyvaso DPI® (treprostinil) Inhalation Powder</b> <small>(marketed by United Therapeutics)</small>	<b>PAH / PH-ILD</b>					Marketed
<b>Nintedanib DPI</b> <small>(MNKD-201)</small>	<b>IPF, PPF</b>					Phase 2 (INFLO-2 study)
<b>Ralinepag DPI (MNKD-1501)</b> <small>(collaboration with United Therapeutics)</small>	<b>PAH, PH-ILD, IPF, PPF</b>	Pre-Clinical				